The association of axillary lymph node-positive breast cancer with metabolic parameters of 18F-fluorodeoxyglucose PET / CT Axillary lymph node positive breast cancer and PET/CT
Article Sidebar
Main Article Content
Abstract
Objective: This study aims to examine the association between 18F-fluorodeoxyglucose PET/CT (18F-FDG PET/CT) metabolic parameters of lymph node-positive and lymph node-negative breast carcinomas.
Material and method: We included breast carcinomas patients who underwent 18F-FDG PET/CT imaging at our department between May 2018 and December 2019. A total of 108 female breast cancer patients were included (aged 48.8 ± 13.6years; range, 28-84 years). PET scanning was performed in 3D mode from the skull ceiling to the half of the thigh. According to pathology reports, we divided the patients into two groups: a lymph node-positive group of patients and a lymph node-negative group of patients. We calculated the sensitivity and specificity for determining the PET/CT pathological lymph node. Metabolic parameters like TLG (Total lesion glycolysis), MTV (Metabolic tumor volume), SUVmean, and SUVmax values were calculated.
Result: The lymph node-positive group’s body weight and body mass index(BMI) were statistically higher than the lymph node-negative group (p=0,027,p=0,022 respectively). SUV max and SUV mean of the lymph node-positive group were statistically higher than the lymph node-negative group (p=0.008, p=0,009, respectively). Both TLG and MTV of the lymph node-positive group were statistically higher than the lymph node-negative group (p=0.01, P= 0.01, respectively). Ki-67(%) of the lymph node-positive group was not statistically different from the lymph node-negative group. We calculated the PET/CT’s sensitivity and specificity as 78,57% and 59,09%, respectively. For the positive predictive value of PET/CT, we found 55%, and for the negative predictive value, it was 81.25%.
Conclusions: PET/CT metabolic parameters of patients with lymph node-positive breast cancer were higher than patients with lymph node-negative. High body weight and BMI appears to increase the possibility of metastases of lymph node. The sensitivity of PET/CT can be considered to be useful in determining the pathological lymph node, but the specificity of PET/CT is not very good.
Downloads
Article Details
Accepted 2020-03-13
Published 2020-03-23
References
World Health Organization International Agency for Research on Cancer. The Global Cancer Observatory. 2018 statistics. http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf (Accessed on January 17, 2019).
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70:7.
de Freitas R Jr, Costa MV, Schneider SV, Nicolau MA, Marussi E. Accuracy of ultrasound and clinical examination in the diagnosis of axillary lymph node metastases in breast cancer. Eur J Surg Oncol 1991; 17:240.
Lanng C, Hoffmann J, Galatius H, Engel U. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer. Eur J Surg Oncol 2007; 33:281.
Vaidya JS, Vyas JJ, Thakur MH, Khandelwal KC, Mittra I. Role of ultrasonography to detect axillary node involvement in operable breast cancer. Eur J Surg Oncol 1996; 22:140.
Fein DA, Fowble BL, Hanlon AL, Hooks MA, Hoffman JP, Sigurdson ER et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997; 65:34.
McGee JM, Youmans R, Clingan F, Malnar K, Bellefeuille C, Berry B. The value of axillary dissection in T1a breast cancer. Am J Surg 1996; 172:501.
S. Shin, K. Pak, D.Y. Park, Kim SJ. Tumor heterogeneity assessed by 18F-FDG-PET/CT is not significantly associated with nodal metastasis in breast cancer patients, Oncol Res Treat 39(1-2) (2016), 61–66.
B.B. Koolen, K.E. Pengel, J. Wesseling, et al. Sequential (18) F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy, Eur J Nucl Med Mol Imaging 2014 41(1);32–40.
Koolen BB, Vrancken Peeters MJ, Wesseling J, Lips EH, Vogel WV, Aukema TS, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1830–8.
Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med. 1998;28:290–302.
Choi BB, KimSH, Kang BJ, Lee JH, Song BJ, Jeong SH, et al. Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma. World J Surg Oncol. 2012;10:126.
Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.
Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P. Correlation of 18F fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun. 2013;34:1055–67.
Gil-Rendo A, Martinez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96:166–70.
Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.
Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15:588–93.
Sanli Y, Kuyumcu S, Ozkan ZG, Isik G, Karanlik H, Guzelbey B. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med. 2012;26:345–50.
Boellaard R, Delgado-Bolton R, Oyen WJ Giammarile F, Tatsch K, Eschner W et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging. 2015;42(2):328-354.
Koolen BB, Valdés Olmos RA, Elkhuizen PHM, Vogel WV, Vrancken Peeters MJ, Rodenhuis S. Locoregional lymph node involvement on 18F‐FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer Res Treat 2012; 135: 231– 240.
Fuster D, Duch J, Paredes P elasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008; 26: 4746– 4751.
Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K. Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools. Oncologist. 2020 Feb;25(2):e231-e242.
Liu, Y. Role of FDG PET-CT in evaluation of locoregional nodal disease for initial staging of breast cancer. World. J. Clin. Oncol. 2014, 5:982-989.
Avril N, Rosé CA, Schelling M Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine‐18 fluorodeoxyglucose: Use and limitations. J Clin Oncol Off J Am Soc Clin Oncol 2000; 18: 3495– 3502.
Kim JY, Lee SH, Kim S , Kang T, Bae YT. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol 2015;25:1172-81.
An, Young-Sil, Kang, Doo Kyoung, Jung, Yongsik , Kim, Tae Hee . Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis Section Editor(s): Zhuang., Hongming
Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M et al. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging 2016;6:120-7. Bibliographic Links 28-Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S et al. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med 2013;2:725-33.
Yoo J, Kim BS, Yoon HJ. Predictive value of primary tumor parameters using 18F-FDG PET/CT for occult lymph node metastasis in breast cancer with clinically negative axillary lymph node. Ann Nucl Med. 2018 Nov;32(9):642-648.
Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010;1:747-754.
Lahmann PH ,Hughes MC, Williams GM, Green AC.: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer. 2004 111(5):762-71,
Blackburn GL, Wang KA. Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS). Am J Clin Nutr. 2007 86(3):s878-81